This week in oncology biotech was marked by Gilead Sciences’ significant $5 billion acquisition of Tubulis GmbH, a developer of next-gen antibody-drug conjugates aimed at precise cancer treatment. The sector also saw Amgen’s tarlatamab receive regulatory approval in China for extensive-stage small cell lung cancer, highlighting the growing global significance of bispecific T-cell engagers. Amidst these developments, experts noted that while oncology financing remains robust, the core challenges lie in the biological understanding of early drug development. This week underscored both the potential for transformative innovations in oncology and the critical intersection of science and strategic investment.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://oncodaily.com/biotech/oncology483389
